Loading
A phase 3 trial testing TBI-1301 in sarcomas, now recruiting.
Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma is a phase 3 interventional study registered as NCT07174427, led by Takara Bio, and recruiting on the registry. Official title: Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma. Planned enrolment is 5 participants (estimated). The study started in 2026-01-05 and primary completion is expected in 2032-03. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CTAG1B, Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/